LaMB - maintenance lapatinib versus placebo after first-line chemotherapy in patients with locally advanced or metastatic bladder cancer

Submission date	Recruitment status No longer recruiting	Prospectively registered		
31/03/2010		[_] Protocol		
Registration date	Overall study status Completed	[] Statistical analysis plan		
31/03/2010		[X] Results		
Last Edited 04/04/2022	Condition category Cancer	Individual participant data		

Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-lapatinib-for-people-with-bladder-cancer-that-has-spread

Contact information

Type(s) Scientific

Contact name Ms Charlotte Rofe

Contact details ECMC, Barts and the London School of Medicine and Dentistry Old Anatomy Building Charterhouse Square London United Kingdom EC1M 6BQ

Additional identifiers

EudraCT/CTIS number 2007-001826-28

IRAS number

ClinicalTrials.gov number NCT00949455

Study information

Scientific Title

A phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after first-line chemotherapy in patients with HER1 and/or HER2 overexpressing locally advanced or metastatic bladder cancer

Acronym

LaMB

Study objectives

Metastatic bladder cancer is treated with platinum analogue based chemotherapy. In this study patients will initially be treated with standard chemotherapy for locally advanced and metastatic bladder cancer. Those patients who have either a response to treatment (Response Evaluation Criteria in Solid Tumours [RECIST] criteria) or stabilisation of disease will go onto the study. Only those patients who are HER1 and/or HER2 positive will be eligible, as previous studies have shown that these individuals are most likely to respond to treatment with lapatinib. Patients will be randomised to receive maintenance therapy with either lapatinib or placebo. Therapy will continue until disease progression, excessive toxicity or patient request, at which point the treatment will be stopped and patients will be treated according to the doctor's discretion.

Ethics approval required

Old ethics approval format

Ethics approval(s) South East Research Ethics Committee, 28/11/2007, ref: 07/H1102/73

Study design

Randomised multicentre double-blinded trial

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s) Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: National Cancer Research Network; Subtopic: Bladder Cancer; Disease: Bladder (advanced)

Interventions

1. Lapatinib

2. Placebo

Dosage given = 1500 mg (6 x 250 mg tablets) per day. Patients will receive treatment until progression of disease. Follow up is continued at doctor's discretion until death.

Intervention Type

Drug

Phase II/III

Drug/device/biological/vaccine name(s)

Lapatinib

Primary outcome measure

Compare progression-free survival (PFS) in patients with HER1 and/or HER2 over expressing stage IV b, measured after the last follow up of the last patient.

Secondary outcome measures

Measured after the last follow up of the last patient: 1. To compare overall survival (OS) between the two groups 2. Evaluate the safety and tolerability

Overall study start date

31/10/2008

Completion date

01/06/2011

Eligibility

Key inclusion criteria

1. Histologically confirmed metastatic or locally advanced stage IV transitional cell carcinoma of the urothelium

2. Able to commence study drug 3 - 8 weeks after completion of 1st line chemotherapy for metastatic bladder cancer

- 3. HER1 and/or HER 2 positive, confirmed by central lab
- 4. Objective response or stable disease following 4 8 cycles of first-line chemotherapy
- 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 3
- 6. Left ventricular ejection fraction (LVEF) within normal range as measured by ECHO or MUGA
- 7. Written informed consent
- 8. Aged over 18 years, either sex

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned Sample Size: 204

Total final enrolment

232

Key exclusion criteria

- 1. Progression with first-line chemotherapy for metastatic disease
- 2. Previous anti-HER1 or HER2 therapy
- 3. More than one line of chemotherapy for metastatic or locally advanced disease
- 4. Significant cardiac disease
- 5. Patients receiving less than 4 or more than 8 cycles of chemotherapy before randomisation
- 6. Major surgery or curative radiotherapy after chemotherapy (palliative radiotherapy is allowed)

Date of first enrolment

31/10/2008

Date of final enrolment 01/06/2011

Locations

Countries of recruitment England

United Kingdom

Study participating centre

ECMC, Barts and the London School of Medicine and Dentistry London United Kingdom EC1M 6BQ

Sponsor information

Organisation

Queen Mary, University of London (UK)

Sponsor details 5 Walden Street Whitechapel London England United Kingdom E1 2EF

Sponsor type University/education

Website http://www.qmul.ac.uk/

ROR https://ror.org/026zzn846

Funder(s)

Funder type Industry

Funder Name GlaxoSmithKline (UK)

Alternative Name(s) GlaxoSmithKline plc., GSK plc., GSK

Funding Body Type Government organisation

Funding Body Subtype For-profit companies (industry)

Location United Kingdom

Results and Publications

Publication and dissemination plan Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2015		Yes	No
Results article	results	01/01/2017		Yes	No
Basic results			20/05/2019	No	No
<u>Plain English results</u>			04/04/2022	No	Yes